Acute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic Leukaemia
Conditions
Keywords
bone marrow, bone marrow transplant, allogeneic, tacrolimus, cyclophosphamide, Blinatumomab
Brief summary
The investigators primary objective is to determine the safety and toxicity of incorporating blinatumomab into the post-allogeneic hematopoietic stem cell transplant (HSCT) maintenance setting for patients with CD19+-B-cell malignancies (Acute Lymphoblastic Leukemia \[ALL\], Non-Hodgkin's Lymphoma \[NHL\]).
Interventions
DRUGBlinatumomab 9ug
Cycle 1 - Days 1-7: 9 ug/day IV daily
DRUGBlinatumomab 28 ug
Cycle 1 - Days 8-28: 28 ug/day IV daily
DRUGBlinatumomab
Cycle 2 - Days 1-28: 28 ug/day IV daily
DRUGDexamethasone
Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
Sponsors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Amgen
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Pre-B ALL, low and high grade NHL who underwent an alloHSCT using posttransplant CY GVHD prophylaxis (Pt-Cy alone or combination with MMF/tacrolimus or sirolimus) as follows: A. Pre-B ALL patients in CR1 with high-risk features such as adverse cytogenetics including t(9;22) or Ph-like ALL, t(4;11) or other MLL (KMT2A) rearrangements, t(v;14q23)/IgH, complex karyotype (≥5 chromosomal abnormalities), hypodiploidy (\<44 chromosomes), low hypodiploidy (30-39 chromosomes)/near triploidy (60-68 chromosomes), intrachromosomal amplification of chromosome 21 (iAMP21), high WBC count at presentation (≥30,000), lack of achievement of complete remission after standard induction chemotherapy (but achieved CR1 following salvage or consolidation), or persistence of detectable disease after induction and consolidation (intensification) or pre-transplant as documented on any of routine clinical tests (morphology, flow cytometry, cytogenetics or molecular studies) OR all Pre-B ALL patients in second and higher CR B. Low and high grade NHL following a nonmyeloablative (reduced-intensity conditioning) transplant irrespective of pre-transplant disease status 2. Patients should be at least 60 but not more than 180 days from transplant with documented count recovery (ANC \>1 x109/L, and non-transfused platelets \>30x109/L) and no evidence of disease progression 3. ECOG performance status 0-2 4. Ability to give informed consent 5. In agreement to use an effective barrier method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy during the study and for a minimum of 30 days after study treatment, for all male and female patients who are fertile 6. Age ≥18 years 7. Patients may have received any number of prior regimens to achieve remission. Patients previously treated with blinatumomab will be eligible as long as they did not experience unacceptable toxicities with prior blinatumomab administration. If patient was refractory (no response) to blinatumomab in the past, patient will be eligible if there was no evidence of CD19 loss on leukemia cells.
Exclusion criteria
1. Lack of engraftment (less than 85% donor DNA in bone marrow or peripheral blood after allogeneic HSCT). 2. Active or untreated disease in central nervous system or testes 3. Patient has received chemotherapy or radiotherapy (with the exception of intrathecal chemotherapy) within 2 weeks of starting blinatumomab. Patient could receive intrathecal prophylactic chemotherapy within a week prior to starting blinatumomab. 4. Patients with active uncontrolled infection or uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. 5. Patients with prior history of severe (grade 3 or 4) acute GVHD or active severe chronic GVHD even if resolved will not be eligible. Patients with history of active acute GVHD (grade 2) and active moderate chronic GVHD who required steroids for the treatment of GVHD will need to be off steroids for at least 4 weeks prior to treatment start. (Topical steroids or physiologic adrenal replacement steroid doses are allowed). 6. Patients requiring calcineurin inhibitors (i.e. tacrolimus or sirolimus) or other systemic immunosuppressants (cyclosporine (CNI); methotrexate or similar) for GVHD prophylaxis or treatment within 4 weeks prior to treatment start. 7. Inadequate end organ function defined as AST, ALT, and alkaline phosphatase \> 3X ULN, bilirubin \>=1.5X ULN, or creatinine \>=2 mg/dL 8. Patients with Ph-positive ALL who are eligible for post-transplant TKI maintenance based on a demonstrated sensitivity to TKIs pre-transplant (patients with known intolerance or resistance to TKI will be eligible) 9. Evidence of progressive disease post-transplant 10. Women who are pregnant or lactating 11. Known hypersensitivity to blinatumomab 12. Patients with a concurrent active malignancy for which they are receiving treatment 13. Concurrent use of any other investigational drugs 14. Patient who have a history or presence of clinically relevant CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, psychosis, or other significant CNS abnormalities. A history of treated CNS leukemia or lymphoma will be allowed if recent imaging and CSF studies confirm the absence of active CNS disease at the time of study entry 15. Weight \<45 kg 16. Patients receiving other post-transplant maintenance therapies 17. Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus (HCV)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival at two years post first treatment cycle | 2 years | Percentage of enrolled participants who receive BMT and Blinatumomab and are alive at two years post BMT. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Non-Relapse Mortality | 2 years | Percentage of participants who experience non-relapse mortality after 2 years. |
| Progression-free survival | 2 years | Percentage of participants who experience progression-free survival after 2 years. |
| Disease-free Survival | 2 years | Percentage of participants who experience disease-free survival after 2 years. |
| Overall Survival | 2 years | Percentage of participants who experience overall survival after 2 years. |
| Minimal Residual Disease | 2 years | Percentage of participants who convert from MRD to no MRD after treatment. |
Countries
United States
Contacts
STUDY_CHAIRIvana Gojo, MD
Johns Hopkins University
PRINCIPAL_INVESTIGATORJonathan Webster, MD
Johns Hopkins University
Outcome results
None listed